Volume 41, Number 5

President’s Report…………...……………………………..……..…….…..…….………………2

Karen Berger, PharmD, BCPS, BCCCP, NYCSHP President

NY State Legislative and NYC Chapter Grassroots Advocacy Update.…..…….………….……3

Andrew Kaplan, PharmD, BCPS, BCGP, VP of Public Policy and Karen Berger,

PharmD, BCPS, BCCCP, NYCSHP President

NYCSHP Grassroots Advocacy Committee Testimonials……………………………. …….…..5

Tinnie Liao-Ng Yan, PharmD Candidate; Matthew Li, PharmD; Joyce Wu, PharmD,

MPH; Jennie Xu, PharmD; Cye Cornelio, PharmD

Antidiabetic Treatment and Cardiovascular Disease Prevention for Type 2 Diabetes…...............6

Dean Gennaro, PharmD Candidate

Niki Patel, Pharm.D., MBA, Preceptor

New Developments in Combating the National Opioid Crisis……….………………….……….9

Rishab Kumar, PharmD Candidate

Charrai Byrd, PharmD, Preceptor

Trivia Questions…….…………………………………………………......…................……….13

Photo Gallery……………….…………………………………………......…................……….15

1

Volume 41, Number 5

President’s Report

Winter may be coming, but our chapter has kept busy in the meantime, kicking off the new academic

year with a bang! Between August and the end of this calendar year, we have provided >8 CE programs

in addition to many networking and community service events. We held our first Clinical and Directors

Roundtable in the fall, which included pharmacy students, residents, clinical pharmacists, operational

managers, and directors of pharmacy from more than 15 different institutions! The Roundtable allowed

everyone to network and share best practices related to hot topics such as managing drug shortages, high

cost medications, antimicrobial stewardship, transitions of care, and collaborative practice agreements.

Due to the overwhelmingly positive feedback we received from this program, we will plan to hold

another roundtable in the spring.

We are also getting more involved in our local community. In October, our chapter participated in NY

Cares Day, with volunteers dedicating time to paint a school in Brooklyn. In November, a group of

NYCSHP members served as medical volunteers in the NYC marathon, helping to sort supplies, draw

up and dispense medications, and triage patients. We are also initiating a partnership with the NYC

Medical Reserve that will lead to future community service collaborations, including brown bag events

and blood pressure screenings. Our chapter donated $500 to the Texas Hospital Association (THA)

Employee Assistance Fund for victims of Hurricane Harvey. We have also formed a team for the 2018

Cycle for Survival taking place this spring where all proceeds go to rare cancer research at Memorial

Sloan Kettering.

Our new Grassroots Advocacy Committee is up and running. The objectives of this committee include:

providing legislative updates to members, increasing advocacy efforts, facilitating new practitioner

engagement, reporting metrics, and collaborating with other pharmacy organizations. Through this

committee, we have been able to provide legislative updates at every NYC chapter event and have set up

nine local legislative visits, partnering junior and seasoned members to lobby together. We held our first

ever Grassroots Advocacy dinner, which provided a primer on the basic steps towards effective

pharmacy advocacy. In January, we plan to hold our second dinner with an update from our new

NYSCHP lobbyist, Senator Spano.

We also continue to facilitate nontraditional networking opportunities, kick-starting the new year with a

LISHP/NYCSHP event at a Mets game, followed by an active shooter training, a new practitioner’s

happy hour, and a fall hike at Breakneck Ridge. The active shooter training was provided by Jin Kim,

Special Agent from the FBI and included many potentially life-saving survival tips. In January, we have

planned a Stop the Bleed program to help bystanders learn the basics of bleeding control in catastrophic

situations. For the spring, we are planning a charity 5K run to engage the runners (and walkers!) in our

chapter, as well as a football scrimmage between our seasoned and new practitioners. We are always

trying to think outside the box for more nontraditional programs that encourage networking in a fun

environment. If you have ideas for future events or have any questions about our chapter, please email

me at karenberger7@gmail.com.

Thank you so much to our outstanding members who have been involved, engaged, and active members

of our society!

Sincerely,

Karen Berger, Pharm D, BCPS, BCCCP; President, NYCSHP

2

Volume 41, Number 5

New York State Legislative Update and NYC Chapter Grassroots Advocacy Update Andrew Kaplan, PharmD, BCPS, BCGP, Vice President of Public Policy, NYSCHP and Karen Berger,

PharmD, BCPS, BCCCP, President, NYCSHP

New York State Council Updates:

NYSCHP has contracted with a new lobbying firm – Empire Strategic Planning – headed by former

New York State Senator Nicholas Spano

Our current legislative priorities include: Technician Registration, CDTM, and Immunization

Expansion

A new toolkit will be posted shortly to help members start the advocacy process

NYSCHP will be getting together with the other Pharmacy Organizations/Stakeholders (PSSNY,

1199, Chain Pharmacy Association) together to rewrite our technician bill

National Legislative Updates:

Pennsylvania and Wisconsin: working on Pharmacy Technician Registration legislation

New Jersey: working on a bill which would require Certification for all technicians

Maine: Pharmacists can now get reimbursed by Medicaid for tobacco cessation services

Maryland: Pharmacists can now prescribe and dispense oral contraceptives

New Hampshire: Pharmacy Interns are now able to administer certain immunizations

Grassroots Advocacy Committee Update:

The new NYCSHP Grassroots Advocacy Committee is up and running! We have engaged NYC

members to meet with nine local legislators regarding Pharmacy Legislation, chiefly our Pharmacy

Technician Registration and Certification bill, with more visits scheduled. New York is one of only 5

states that does not regulate technicians. Most of our Assembly Representatives were not aware of this

issue and that our legislation would protect our communities by requiring Registration and Certification.

In fact, they were all interested or supportive of passage of the legislation and some – after hearing about

it from us for the first time – agreed to be co-sponsors! This demonstrates that with the thousands of

issues our Representatives face any given year, it is of critical importance to make your voice heard. If

you are interested in meeting with your legislator, but are not sure how to start the process, please reach

out to us and we will guide you through the process. We are hopeful that every member will participate

in our grassroots advocacy efforts this year!

3

Volume 41, Number 5

Legislative Visits initiated through the Grassroots Advocacy Committee:

Legislator Date NYCSHP

Members

Position

Assembly Member

Robert Rodriguez

(D – District 68)

9/25/17 Joyce Wu

Andrew Kaplan

Mr. Rodriguez’s Chief of Staff and Legislative

Affairs Director stated the Assemblyman would

likely co-sponsor the legislation; they offered to do a

press conference with us in Albany about the issue

Assembly Member

Robert Carroll

(D – District 44)

10/11/17 Tinnie Liao-Ng

Yan

Andrew Kaplan

Mr. Carroll said he would be happy to support the

legislation

Assembly Member

Francisco Moya

(D – District 39)

10/20/17 Jennie Xu Mr. Moya’s Deputy Director was interested in the

legislation; would run it by the Assemblyman

Assembly Member

Shelley Mayer

(D – District 90)

10/25/17 Cyrille Cornelio

Andrew Kaplan

Ms. Mayer said she would be glad to support the

legislation

Assembly Member

Michael Miller

(D – District 39)

10/26/17 Matthew Li

Andrew Kaplan

Mr. Miller said he would be happy to be a co-

sponsor

Assembly Member

Rebecca Seawright

(D – District 76)

11/16/17 Yi Guo

Jessica Snead

Andrew Kaplan

Karen Berger

Ms. Seawright said she would be happy to co-

sponsor the legislation

Assembly Member

Brian Curran

(R – District 21)

11/29/17 Jamie Chin

Andrew Kaplan

Mr. Curran said he would gladly co-sponsor the

legislation

Assembly Member

Edward Braunstein

(D – District 26)

11/29/17 Jimmy Seo

Joe Pinto

Mr. Braunstein’s Special Assistant stated his eyes

were opened to this issue and that the bill should be

passed; he will speak to the Assembly Member

about it

Assembly Member

Nily Rozic

(D – District 25)

12/11/17 George

Rodriguez

Andrew Kaplan

Ms. Rozic’s Legislative Affairs and

Communications Director stated they saw no reason

why the Assembly Member would not co-sponsor

the legislation

Your Legislator Soon! YOU!

4

New York City Society of Health-System Pharmacists - Grassroots Advocacy Committee Testimonials

Tinnie Liao-Ng Yan, BS, MSc; Touro College of Pharmacy Pharm.D. Candidate, Class of 2019

Met with Assemblyman Robert Carrol (D) – 44th

Assembly District

I was motivated by NYCSHP Grassroots Committee’s vision and felt the importance of advocating for my

profession. Living in Brooklyn all my life, I had no idea my Assemblyman had an office so easily accessible and

that they will be willing to listen to me.

For my appointment, it was arranged that I would be accompanied by a seasoned Committee member (Andrew).

As a third year student at Touro College of Pharmacy and first time “grassroots advocate”, I was nervous! I would

have been unlikely to have gone by myself. Andrew provided me with some “talking points” to help focus the

conversation, and asked me to familiarize myself with the pharmacies in my Assembly district to illustrate the

impact the legislation would have on the local community.

Matthew Li, Pharm.D.; PGY-1 Pharmacy Resident, James J. Peters VA Medical Center:

Met with Assemblyman Michael Miller (D) – 38th

Assembly District

The meeting was successful. The Assemblyman opened up to us about his own experiences with pharmacists and

the importance of having competent staff. He admitted that he was initially not familiar with the difference

between a pharmacist and a technician, and that he was shocked to discover anyone in New York State could be

hired as a technician and handle prescriptions. At the end of the discussion, Mr. Miller stated he was supportive of

registration and certification for pharmacy technicians, and wanted to look into the legislation further.

Joyce Wu, Pharm D, RPh, MPH; Memorial Sloan Kettering Cancer Center:

Met with staff of Assemblyman Robert Rodriguez (D) – 68th

Assembly District

The staff asked some good questions regarding the impact the legislation would have on the public and the local

community; they also asked about potential financial impact to technicians. Once we got our points across,

bringing our own Pharmacy practice experiences, they offered to co-sponsor the bill. The experience was great

and I’m confident our grassroots efforts will soon be put to great use in making more changes and impact to our

profession.

Jennie Xu, Pharm.D.:

Met with staff of Assemblyman Francisco Moya (D) – 39th

Assembly District

The preparatory work was very helpful. I actually went by myself and met with the Deputy Director of the

District office. She stated the office would be supportive of the Technician legislation and would speak to the

Assemblyman about it.

Cye Cornelio, Pharm.D.; PGY-1 Pharmacy Resident, Montefiore Medical Center:

Met with Assemblywoman Shelley Mayer (D) – 90th

Assembly District As with any new experience, I was nervous about articulating myself effectively and representing the profession

well. However, the committee’s buddy system and prep time with Andrew made this day less nerve-wracking.

Our meeting with Assemblywoman Mayer went very well! She expressed a genuine interest in our profession and

understood the importance of having a pharmacy technician registry. She provided advice on next steps that we

should take, suggested that we reach out to the other assembly member in Yonkers, and even offered for us to

reach out to her again for future support on other bills!

5

Did you know?

Patients with diabetes have a 2-6

times higher risk of mortality from

CV events. Providers target the

ABCs: A1c, Blood pressure &

Cholesterol… but is that enough to

decrease the risk of mortality?

Antidiabetic Treatment and Cardiovascular Disease Prevention for Type 2 Diabetes

Dean Gennaro, Pharm.D. Candidate, 2018 Arnold and Marie Schwartz College of Pharmacy LIU

Preceptor: Niki Patel, Pharm.D., MBA, Adjunct Assistant Professor, LIU

From 2003-2006, death rates from cardiovascular disease (CVD) were

approximately 1.7 times higher in patients with diabetes versus those without

diabetes1,2

. Heart attacks are 1.8 times more likely to occur in patients aged 20

and older with diabetes than those without diabetes2. Due to the increased risk

of cardiac outcomes and death in this population, agents that either

demonstrate CV benefit or safety should be considered in patients with a

history of CVD. Here we present updates and previous data on cardiovascular

outcomes for common type 2 diabetes medications for clinicians to make

informed decisions.

Based on a 2008 FDA guidance, pharmaceutical companies were required to conduct cardiovascular outcomes trials

(CVOTs) to demonstrate safety of the diabetes agents3. The EMPA-REG (empagliflozin), CANVAS (canagliflozin),

LEADER (liraglutide) and SUSTAIN-6 (semaglutide) studies all have shown statistically significant reductions in their

primary endpoints of reducing death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke

compared to placebo4-6

.

GLP1: Liraglutide’s LEADER study demonstrated 13% reduction in CVO while semaglutide’s SUSTAIN-6

demonostrated 26% reduction in CVO4,5

. Lixisenatide’s ELIXA (not shown) was found to be neutral.

SGLT2: The 1st diabetes trial to show CV benefit was EMPA-REG demonstrating a 14% reduction in CVO and decreased

renal outcomes6. Most recently in June 2017, CANVAS data showed 14% reduction in cardiovascular outcomes, however

the cardio-renal benefit was accompanied with doubled risk of amputations (HR 1.97; 95% CI 1.41–2.75), primarily at

the level of the metatarsal or toe7.

6

DPP4s: Alternatively, the CVOTs for sitagliptin, alogliptin and saxagliptin did not demonstrate a cardiovascular benefit8-

11. Moreover, the FDA in 2016 added a warning for alogliptin and saxagliptin-containing medicines for potential increased

risk of heart failure, particularly in patients who already have heart or kidney disease12

.

SAVOR EXAMINE TECOS

Saxagliptin vs. PBO Alogliptin vs. PBO Sitagliptin vs. PBO

No difference in CVO

Higher incidence of

hospitalization for HF in

saxagliptin

No difference in CVO

Increased rates of HF

No difference in CVO

Thiazolidinedione (TZD): Several meta-analyses of pioglitazone has shown reductions in macrovascular events, showing

reductions in all-cause mortality, MI, and stroke compared to placebo but increases heart failure risk. Unfortunately, this

wasn’t the same case for rosiglitazone which showed an increase risk of macrovascular events from several other

studies13

.

Sulfonylureas (SU): There are no RCTs evaluating their CV outcomes for SUs.14

In one study versus metformin, SUs had

an increase of cardiovascular events15-16

. A recent study has found a 32% greater risk for heart failure with sulfonylurea

treatment vs. metformin therapy14

. A meta-analysis of RCTs found that sulfonylureas confer a 46% greater risk for CV

mortality and a 26% greater risk for all-cause mortality vs. placebo. The exception is glimepiride which has shown to be

safe for cardiovascular risk at low doses and the SU of choice for diabetes patients with underlying coronary artery

disease.

We await the results of GRADE and CAROLINA studies to determine the verdict on SUs. GRADE assesses the long term

outcomes of four diabetes treatments head-to-head; CAROLINA is a CVOT assessing DPP4 linagliptin versus

glimepiride. Considering these factors and risk of hypoglycemia and as other therapies become generic, will SU’s fall out

of practice?

Updated guidelines: AACE has updated their guidelines and profile of diabetes medications to reflect the recent data.

The ADA 2017 guidelines added a recommendation to consider empagliflozin or liraglutide in patients with established

cardiovascular disease to reduce the risk of mortality17

.

In summary, in treating patients with type 2 diabetes and cardiovascular disease, healthcare professionals should assess

cardiovascular risk and consider agents that reduce the risk of cardiovascular mortality.

7

References:

1) Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and

management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012;60(24):e44-e164.

2) Statistics About Diabetes. American Diabetes Association. http://www.diabetes.org/diabetes-

basics/statistics/?referrer=https%3A%2F%2Fwww.google.com%2F. Accessed June 11, 2017.

3) Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat

Type 2 Diabetes. https://www.fda.gov/downloads/Drugs/.../Guidances/ucm071627.pdf. Updated December 2008.

Accessed June 11, 2017.

4) Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl

J Med. 2016;375(4):311-22.

5) Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N

Engl J Med. 2016;

6) Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N

Engl J Med. 2016;374(11):1094.

7) Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes N

Engl J Med. 2017;377(7):664-657.

8) Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N

Engl J Med. 2015;373(23):2247-57.

9) Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N

Engl J Med. 2015;373(3):232-42.

10) White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N

Engl J Med. 2013;369(14):1327-35.

11) Cavender MA, Scirica BM, Raz I, et al. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline

Hemoglobin A1c. Am J Med. 2016;129(3):340.e1-8.

12) Commissioner of the. Safety Alerts for Human Medical Products - Diabetes Medications Containing Saxagliptin and

Alogliptin: Drug Safety Communication - Risk of Heart Failure. U S Food and Drug Administration Home Page.

https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm494252.htm. Accessed

June 11, 2017.

13) Erdmann E, Charbonnel B, Wilcox R. Thiazolidinediones and Cardiovascular Risk — A Question of Balance. Curr

Cardiol Rev. 2009;5(3): 155–165.

14) Katsiki N et al. Cardiovascular disease prevention strategies for type 2 diabetes. Expert Opin Pharmacother.

2017;18(12):1243-1260.

15) Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on

risk of cardiovascular events in type 2 diabetes mellitus. Ann Intern Med. 2012 Nov 6;157(9):601-10

16) Roumie CL, Min JY, McGowan LDA, et al. Comparative Safety of Sulfonylurea and Metformin Monotherapy on the

Risk of Heart Failure: A Cohort Study. J Am Heart Assoc. 2017 Apr 19;6(4)

17)Standards of Medical Care in Diabetes - 2017. Diabetes Care.

http://professional.diabetes.org/sites/professional.diabetes.org/files/media/dc_40_s1_final.pdf. Published January 2017.

Accessed June 11, 2017.

8

New Developments in Combating the National Opioid Crisis

Rishab Kumar, Pharm.D Candidate 2018

Charrai Byrd, Pharm.D

Arnold & Marie Schwartz College of Pharmacy and Health Sciences

New York Presbyterian Hospital- Columbia University Irving Medical Center

The opioid epidemic in the United States has achieved nationwide attention as it has infiltrated

thousands of communities across the country, affecting millions of American lives daily. Prescription drug

abuse has nearly quadrupled in the past decade, leading to an unprecedented rate of overdose-related deaths.

According to a 2015 study conducted by the National Survey on Drug Use and Health (SAMHSA),

approximately 12.5 million Americans abused opioids, which resulted in over 33,000 deaths.1

Healthcare costs

for managing the crisis resulted in approximately 78 billion dollars spent, with estimates of escalating costs and

higher mortality rates every year.2 The Centers for Disease Control and Prevention (CDC) also projects that

approximately 1,000 Americans are treated daily in the emergency department for opioid-related overdoses,

resulting in over 90 opioid-related deaths per day.3 The economic and social ramifications of this public

epidemic have led to key government agencies paying closer attention to this important issue, as well as

diverting additional resources and funds in expanding medical care.

On October 26 2017, Acting Health and Human Services (HHS) Secretary Eric D. Hargan declared a

nationwide public health emergency to combat the opioid crisis, as requested by President Donald Trump and

recommended by the President’s Commission on Combating Drug Addiction and Opioid Crisis.4 This

declaration is an important step forward in raising addiction awareness and will subsequently increase

utilization of funds and resources dedicated in combating this escalating crisis. Under the public health

emergency, several executive agencies and key stakeholders would be required to use all appropriate emergency

resources to tackle opioid addiction. Furthermore, additional funds will be available from the federal

government and provided to state and local governments for expanding treatment options for addicts. These

9

options include raising awareness for prevention, treatment, and support services, relaxing federal regulations

for Medicaid members seeking treatment, researching new addiction treatments and pain management

strategies, accelerate appointments of personnel equipped with tackling the crisis, and increasing access to

lifesaving medications, such as naloxone, for emergency responders.4 The administration may also request

Congress to formally allocate additional funds in their spending budget, therefore a certain monetary amount is

set aside annually for expanding additional treatment options.4

The U.S. Drug Enforcement Administration (DEA) has also stepped up their efforts in curbing substance

abuse by proposing a further 20% reduction in the manufacturing of more than 250 Schedule I & II controlled

substances in the United States for fiscal year (FY) 2018, as compared to FY 2017 limits.5

The Aggregate

Production Quotas (APQ) reflect the total amount of controlled substances the DEA deems necessary for

manufacturing to address the legitimate medical, scientific, experiential, or industrial opioid needs of the United

States.6 The APQ was established under the Controlled Substance Act, and designates the DEA administrator to

set annual quota limits on the manufacturing of Schedule I & II substances in order to reduce or eliminate the

diversion of opioids, meanwhile continuing the uninterrupted supply of these medications for patients with

legitimate needs.6 This reduction stems from data gathered by outside agencies such as IMS Health, which

supply the DEA with statistics on opioid prescriptions written and sold in the United States.6 Because

establishing a quota system can have a profound effect for legitimate users, the DEA works in close

coordination with the U.S. Food and Drug Administration (FDA) and analyzes data from many agencies and

estimates retail consumption from community pharmacies, internal DEA monitoring system, and finally

manufacture disposition history.5

Pharmacists are an integral part of the national response to the opioid epidemic and can serve in various

capacities to limit diversion and ensure appropriate medication use. As inpatient providers, pharmacists can

screen patients who have a past history of opioid use by asking open-ended questions with patients to assess

their medication usage and detect patterns of misuse or addiction.7 Pharmacists in the outpatient setting also

have a variety of methods to limit opioid misuse. Routine utilization of statewide prescription monitoring

programs is an important screening tool that provides a patient’s history of controlled substances use.7 This

option may limit doctor shopping, early refills, and ensure that a patient is taking their controlled substance

appropriately, as prescribed by their caretaker. Pharmacists can also incorporate routine opioid screenings in

their daily workflow at community pharmacies to ensure these medications are being prescribed in accordance

with current clinical practice and national guidelines. For example, compliance with the CDC’s

recommendation to limit duration of opioid treatment to less than seven days for an acute incident can be

important in mitigating diversion and preventing substance abuse.8 If prescriptions are being issued for an

incident that does not warrant an extended therapy, pharmacists can actively intervene in such cases to educate

practitioners about the risks for a potential overuse and therefore limit the quantity prescribed. Pharmacists can

also serve as important educators of proper drug storage. Recent studies have concluded that patients are not

properly educated on appropriate medication storage and disposal, which may give rise to diversion and

improper use. Counseling patients on the severity of misuse and safeguarding their medications is an important

step forward in deterring opioid abuse and misuse.

Combating the opioid epidemic requires nationwide attention due to alarming and unprecedented rate at

which it is growing in communities across the country. Resources and assistance from federal, state, as well as

local authorities is absolutely essential in beginning new treatment options and ultimately reducing overdose-

10

related mortality. It is imperative that as healthcare providers, pharmacists exercise routine screening of such

cases where substance abuse is suspected and take actions to limit opioid abuse and diversion.

References:

1- Center for Behavioral Health Statistics and Quality. Results from the 2015 National Survey on Drug Use

and Health: Detailed Tables. Substance Abuse and Mental Health Services Administration.

https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-

2015/NSDUH-DetTabs-2015.pdf. Published September 2016. Accessed August 25, 2017.

2- Opioid Overdose: Prescription Opioid Overdose Data. Center for Disease Control and Prevention.

https://www.cdc.gov/drugoverdose/data/overdose.html. Accessed November 4, 2017.

3- Assistant Secretary for Public Affairs. The U.S. Opioid Epidemic. HHS.gov

https://www.hhs.gov/opioids/about-the-epidemic/index.html#. Updated August 2017. Accessed

November 4, 2017.

4- HHS Press Office. HHS Acting Secretary Declares Public Health Emergency to Address National

Opioid Crisis. U.S. Department of Health and Human Services.

https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-

address-national-opioid-crisis.html. Published October 27, 2017. Accessed November 4, 2017.

5- Barrett J. DEA Proposes Reducing Opioid Manufacturing for 2018. Pharmacy Times.

http://www.pharmacytimes.com/news/dea-proposes-reducing-opioid-manufacturing-for-2018. Published

August 4, 2017. Accessed November 4, 2017.

6- Federal Registrar. Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances

and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and

Phenylpropanolamine for 2018. Drug Enforcement Administration.

https://www.federalregister.gov/documents/2017/08/07/2017-16439/proposed-aggregate-production-

quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of. Published August 7, 2017.

Accessed November 4, 2017.

7- Reynolds V, Causey H, McKee J, Reinstein V, et al. The Role of Pharmacists in the Opioid Epidemic-

An Examination of Pharmacist-Focused Initiatives across the United States and North Carolina. N C

Med J. 2017; 78(3):202-205. Accessed August 25, 2017.

8- Dowell D, Haegerich T, Chou Robert. CDC Guideline for Prescribing Opioids for Chronic Pain —

United States, 2016. Centers for Disease Control and Prevention.

https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm#suggestedcitation. Published March 18, 2016.

Accessed November 4, 2017

11

CALL FOR PAPERS Have you wanted to publish, but never had a chance?

We are looking for articles in all areas of pharmacy

practice!

Please submit your publications to the bulletin editors: Sasha Falbaum alexandra11229@gmail.com

Alla Khaytin alla_melamed@yahoo.com William Olsufka williamolsufka@gmail.com

12

1. What is the first combination of an antipsychotic and an antidepressant in one tablet?

2. What is the only medication FDA approved for Bulimia Nervosa? 3. The first licensed pharmacist set up shop in which U.S. city?

13

NYCSHP Board Members President Karen Berger kab9098@nyp.org

President-Elect Charrai Byrd chb9050@nyp.org Immediate Past-President Jason Babby jason.babby@mountsinai.org

Secretary Zane Last zlast@sbhny.org Treasurer Amber Johnson ajohnson01@mail.rockefeller.edu

Director at Large-Constitution & Bylaws, Public Relations, Special

Projects Nikki Bhogal Nikki.Bhogal@mountsinai.org

Director at Large-Student Relations, Legislative Affairs, Supportive

Personnel Maabo Kludze mkludze@GNYHA.org

Director at Large-Installation, Membership, Industry Relation

Harshal Shukla

HSHUKLA@montefiore.org

Other Committees Chairs

Bulletin Editors Alla Khaytin

Sasha Libman William Olsufka

alla_melamed@yahoo.com alexandra11229@gmail.com william.olsufka@touro.edu

Community Outreach George Falbaum George.Falbaum@mountsinai.org Grant Writing Evangelina Berrios-Colon Evangelina.Berrios-Colon@touro.edu

Social Media Coordinator Elsie Wong elsie.wong922@gmail.com

Historian Johnny Hon Jamie Chin

johnnyjhon@gmail.com jamiehchin@gmail.com

New Practitioner Committee Nidhi Saraiya Milan Sharma

nidhi.saraiya@gmail.com milan.sharma1010@gmail.com

Liaisons

State Liaisons Andrew Kaplan, Joe Pinto,

Leila Tibi-Scherl

Faculty Liaisons

William Olsufka (Touro

College of Pharmacy), Khusbu Patel (St. John’s University), Antony Pham (Long Island

University)

14

Clinical and Director Roundtable Event

15

Volume 41, Number 5

Fall Board of Director’s Meeting

16

Volume 41, Number 5

NYCSHP Breakneck Ridge Hike

NYCSHP’S GRASSROOT LOBBYING COMMITTEE IN ACTION!

Tinnie Liao-Ng Yan, BS, MSc; Touro College of Pharmacy Pharm.D. Candidate, Class of 2019 Met with

Assemblyman Robert Carrol (D) – 44th Assembly District

17

Volume 41, Number 5

Matthew Li, Pharm.D.; PGY-1 Pharmacy Resident, James J. Peters VA Medical Center: Met with

Assemblyman Michael Miller (D) – 38th Assembly District

Joyce Wu, Pharm D, RPh, MPH; Memorial Sloan Kettering Cancer Center: Met with staff of

Assemblyman Robert Rodriguez (D) – 68th Assembly District

18

Volume 41, Number 5

Celebrating Pharmacy Week at the Today Show!

19

Volume 41, Number 5

NYCSHP Featured at the 2017 NYC Marathon

20

Volume 41, Number 5

Legislative Visits: October 2017 with Assembly Member Shelley Mayer

21

Volume 41, Number 5

Legislative Visits: November 2017 with Assembly Member Rebecca Seawright

22